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Abstract 
Purpose: Stability of the crystalline lens requires formation of microfibril bundles and their 
higher-order structures of ciliary zonules. Trauma, malformation, or degeneration of the ciliary 
zonules can lead to dislocation or displacement of the lens, which in turn can cause transient or 
permanent loss of visual acuity. The purpose of this study was to identify the predicted 
substrates of ASPH, a 2-oxoglutarate- and Fe2+-dependent hydroxylase, which may account for 
the lens instability phenotype of ASPH-associated syndromes. 
Methods: A single proband of European ancestry with spherophakia and high myopia was 
subjected to exome sequencing. Proteins containing the ASPH hydroxylation motif were 
identified within the SwissProt protein database. 
Results: We identified 105 putative substrates of ASPH-mediated hydroxylation in the human 
proteome, of which two (FBN1 and LTBP2) are associated with inherited ectopia lentis 
syndromes, and are essential for microfibril and ciliary zonule development.  
Conclusion: Our results implicate ASPH-mediated hydroxylation in the formation of 
FBN1/LTBP2 microfibril bundles and competent ciliary zonules. 
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 Introduction 
Ectopia lentis is the dislocation or displacement of the crystalline lens, and can lead to 
significant refractive error, pupillary block with associated glaucoma, retinal damage, and in 
some instances, blindness. Ectopia lentis may be secondary to ocular trauma 1, but may be also 
be primary, in which case it is typically bilateral and associated with congenital weakness of the 
ciliary zonules which hold the lens in place. Marfan syndrome is the most common cause of 
primary ectopia lentis, and is associated with heterozygous variants in the fibrillin-1 gene 
(FBN1). 
 
Traboulsi syndrome, also known as FDLAB syndrome (facial dysmorphism, lens dislocation, 
anterior-segment abnormalities, and spontaneous filtering blebs), is a rare ocular malformation 
syndrome associated with ectopia lentis 2,3,4,5,6. FDLAB syndrome is caused by biallelic variants 
at the ASPH locus 5, which encodes at least three unique proteins: junctin, junctate, and 
aspartyl/asparaginyl hydroxylase (ASPH) 7. All variants associated with FDLAB syndrome 
uniquely affect APSH, which encodes a 2-oxoglutarate-dependent oxygenase enzyme that 
catalyzes C-3 hydroxylation of aspartic acid and asparagine residues in the endoplasmic 
reticulum 8. The 2-oxoglutarate-dependent oxygenases are a family of non-heme, Fe2+-
dependent enzymes, and include several essential regulators of oxygen homeostasis via the 
transcription factor HIF (hypoxia-inducible factor) 9. 
 
With only five pedigrees and three pathogenic variants reported to date, there is little 
understanding of the phenotypic spectrum and mechanistic processes associated with biallelic 
variation in ASPH. We describe an individual with compound heterozygous ASPH variants, and 
explore the mechanism by which ASPH promotes lens stability. 
 
 
Material & Methods 
Human subjects 
Patients and family members provided written informed consent under protocols approved by 
the Southern Adelaide Clinical Human Research Ethics Committee (305-08). 
 
DNA sequencing and analysis 
DNA was prepared from whole blood and sequenced as previously described (Siggs et al. 2018, 
JAMA Ophthalmology, in press). 
 
Protein sequence analysis 
Protein sequences were aligned with Clustal Omega and BOXSHADE. Structural analysis was 
performed using PDB structure 5JQY in UCSF Chimera. Putative ASPH substrates were 
identified by searching the SwissProt database for the consensus hydroxylation motif (C-x-[DN]-
x(4)-[FY]-x-C-x-C) in genome.jp/tools/motif/MOTIF2.html. 
 
 
Results 
We identified a single individual who presented at 16 years of age with bilateral high myopia, 
shallow anterior chambers, spherophakia, and closed iridocorneal angles (Figure 1B-D). She 
was of non-consanguineous European ancestry, with no family history of early-onset eye 
 disease. Mild ocular hypertension was observed (maximum intraocular pressure of 23 mm Hg 
bilaterally), as were thin corneas (534/519 μm), and vertical cup:disc ratios were 0.6 bilaterally 
(Supplementary Table 1). Her facial appearance was remarkable for retrognathia and a beaked 
nose, and dental malocclusion (Figure 1E-F). She had no apparent cardiovascular or skeletal 
abnormalities, and was of average height. 
 
To test for the presence of an underlying genetic cause of her condition, DNA isolated from 
peripheral blood was subjected to exome sequencing. We considered the subset of variants 
with a gnomAD r2.0.2 allele frequency < 0.0001. Of those variants predicted to be nonsense, 
essential splice, missense, frameshift, or in-frame insertions or deletions, 8 were compatible 
with a recessive mode of inheritance, including two rare coding variants of uncertain phase were 
identified in ASPH, both of which were predicted to be deleterious by PolyPhen2, SIFT, and 
CADD algorithms (Supplementary Table 2). Parental sequencing subsequently confirmed these 
variants to be in trans in the proband (Figure 2A, B). Given the phenotypic similarities of this 
patient with previously described cases of ASPH-associated disease 5, we considered these 
variants to be a likely explanation for the patient’s phenotype. 
 
Both variants (p.Cys641Ter and p.Arg735Gln) were located in the C-terminal catalytic domain of 
ASPH, which is unique to ASPH and absent from the junctin and junctate protein isoforms 
(Figure 2C). One of these variants (p.Cys641Ter) was a premature termination codon and 
predicted loss-of-function allele, while the second (p.Arg735Gln) was a missense substitution at 
a critical catalytic domain residue. A different substitution at the same residue (p.Arg735Trp) 
was reported in homozygous form in two Lebanese individuals with FDLAB syndrome 3–5. 
 
Arg735 is conserved across vertebrates and invertebrates (Figure 2E), and forms two critical 
salt bridges with an essential cofactor (2-oxoglutarate). 2-oxoglutarate in turn helps coordinate a 
catalytic Fe2+ ion, and recruitment of the aspartic acid or asparagine substrate for hydroxylation 
(Figure 2F). As is the case with p.Arg735Trp, p.Arg735Gln is predicted to abolish 2-oxoglutarate 
binding, and therefore eliminate all catalytic activity of ASPH.  
 
ASPH hydroxylates aspartic acid and asparagine substrates within a defined consensus motif 
(C-x-[DN]-x(4)-[FY]-x-C-x-C) 10. We searched the SwissProt database for all human proteins 
containing the ASPH hydroxylation motif, revealing 105 putative targets (Supplementary Table 
3). These included the vitamin K-dependent coagulation factors VII, IX, X, protein C, and protein 
S; the low- and very low-density lipoprotein receptors; thyroid peroxidase (TPO); complement 
components C1R and C1S; and ligands (JAG1, JAG2) and receptors (NOTCH1-4) of the Notch 
family. Measurements of coagulation, lipoprotein homeostasis, thyroid function, and the 
complement cascade were all within normal limits in peripheral blood samples from the proband 
(Supplementary Table 4), suggesting that ASPH hydroxylation may be physiologically 
redundant in these settings. 
 
There were two predicted ASPH substrates, latent transforming growth factor beta binding 
protein-2 (LTBP2) and fibrillin-1 (FBN1), which were of particular interest, given that variants in 
the genes encoding them are associated with Mendelian syndromes with stark phenotypic 
similarities to FDLAB syndrome. Heterozygous variants in FBN1 cause Marfan syndrome: a 
common cause of primary ectopia lentis 11. Similarly, homozygous or compound heterozygous 
 variation in LTBP2 is associated with microspherophakia, ectopia lentis, and in some instances, 
with secondary glaucoma 12–14. FBN1 and LTBP2 have two of highest numbers of predicted 
ASPH hydroxylation sites, at 43 and 13 sites respectively (Figure 3A). All of these motifs fall 
within EGF-like domains, and all but one are of the calcium-binding EGF-like (cbEGF) subtype 
(Figure 3B). 
 
Discussion 
We provide evidence that biallelic ASPH variants can be associated with a unique syndrome of 
spherophakia, high myopia, shallow anterior chambers, and a distinct facial appearance. The 
individual described in this study had not developed ectopia lentis, iris atrophy, or spontaneous 
filtering blebs by the age of 17, making her presentation distinct from classical FDLAB 
syndrome, although these features may still emerge with age, particularly given that 
spherophakia often precedes ectopia lentis. Dental malocclusion had been described previously 
2,3, and in this case manifested as a maxillary ectopic canine. Of note is the association with 
cholesteatoma, often associated with craniofacial abnormalities, although not described 
previously in ASPH-associated disease.  
 
Of the 105 putative ASPH substrates identified here, the closest phenotypic overlap is with 
LTBP2 and FBN1, both of which are associated with Mendelian syndromes with ocular and 
lenticular phenotypes. Importantly, other proteins implicated in syndromic or isolated forms 
ectopia lentis (ADAMTSL4, ADAMTS10, and ADAMTS17) did not harbor the ASPH consensus 
hydroxylation motif, indicating that ASPH has a much narrower substrate specificity than 
previously expected 5. 
 
LTBP2 and FBN1 are interacting members of the LTBP-fibrillin extracellular matrix (ECM) 
glycoprotein superfamily, sharing 25% homology, and bind directly to one another in a calcium-
dependent manner 15. Their domain structure is rich in calcium-binding epidermal growth factor-
like (cbEGF) domains, interspersed with TGF-β binding protein-like (TB) domains. FBN1 is a 
key structural component of extracellular microfibrils present in the skin, lung, kidney, 
vasculature, cartilage, tendon, muscle, cornea, and ciliary zonule 16, while both FBN1 and 
LTBP2 act in unison to support formation of ciliary zonules 17. Asparagine hydroxylation has 
been observed in FBN1 extracted from human amnion 18, although the functional significance of 
hydroxylation is yet to be determined. 
 
Our data suggest that ASPH-associated lenticular abnormalities, and perhaps other 
phenotypes, are secondary to reduced hydroxylation of LTBP2 and/or FBN1, which in turn 
disrupts microfibril formation, ciliary zonule structure, and ultimately reduce stability of the lens 
17.  
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Figure 1. Craniofacial and anterior segment dysgenesis phenotypes associated with 
biallelic ASPH variants 
 
 
 
Slit lamp examination of the proband (left panels) and her unaffected sister (right panels) 
revealed mid-dilatation of both pupils (A), and bilateral shallow central (B) and peripheral (C) 
anterior chambers in the proband. Anterior segment optical coherence tomography (D) revealed 
bilateral spherophakia, anterior iris convexity, an anterior lens vault, and iridocorneal apposition 
(yellow asterisks). Portrait and profile of the proband (E), with images of a maxillary ectopic 
canine (F, yellow arrow). 
  
Figure 2. Biallelic ASPH variants 
 
 
 
(A) Pedigree of the family described in this study. Round symbols indicate females; square 
symbols, males; black symbols, affected; arrow, proband; +, reference allele. 
(B) Sanger sequencing traces 
(C) ASPH locus and position of disease-associated variants described in this study, and others 
5. Exons shared with the junctate and junctin isoforms are highlighted in purple or red. 
(D) ASPH protein schematic and domain structure, showing location of disease-associated 
missense, nonsense, and frameshift variants. TM, transmembrane domain; TPR, 
tetratricopeptide repeat. 
(E) ASPH protein sequence alignments across multiple model organisms. Arginine 735 is 
highlighted. 
(F) X-ray crystal structure of ASPH with Factor X peptide (PDB: 5JQY). Active site magnified, 
showing Arginine 735 (red), manganese ion (purple), N-oxalylglycine (yellow), and Factor X 
peptide with aspartate substrate (blue). 
 
  
 Figure 3. Predicted ASPH substrates and hydroxylation motif density 
 
 
 
(A) Abundance of ASPH consensus hydroxylation mofits (C-x-[DN]-x(4)-[FY]-x-C-x-C) within 
105 human proteins. Proteins with 10 or more motifs are labelled, and those implicated in 
Mendelian ectopia lentis conditions are highlighted in red. 
(B) Domain architecture of LTBP2 and FBN1 proteins, indicating the location of the ASPH 
consensus hydroxylation mofit (arrows). All but one of these motifs are located in calcium-
binding EGF-like domains. 
 
 
  
 Supplementary Data 
 
Supplementary Table 1. Clinical details of proband with compound heterozygous ASPH 
variants 
RE, right eye; LE, left eye; BCVA, best corrected visual acuity; AC, anterior chamber; IOP, 
intraocular pressure; CCT, central corneal thickness; PI, peripheral iridotomy. 
 
 Family 1 
ID II:1  II:2  
Sex F  F  
Ancestry European  European  
Consanguinity no  no  
Age at diagnosis (y) 16  -  
Age at last follow-up 
(y) 18  23  
Facial dysmorphism beaked nose, retrognathia -  
Dental malocclusion left maxillary ectopic canine -  
Other features dermoid cyst, cholesteatoma, -  
 posterior fossa arachnoid cysts   
Eye RE LE RE LE 
BCVA 6/7.6 6/9.5 6/6 6/6 
Refraction (D) -4.50 -6.00 +0.25 -0.50 
AC depth (mm) 2.17 2.16 - - 
Ectopia lentis no no - - 
Spherophakia yes yes - - 
Filtering blebs no no - - 
Corectopia no no - - 
Iris stromal hypoplasia no no - - 
Iris transillumination no no - - 
Iridocorneal angle closed closed - - 
Posterior embryotoxon no no - - 
Vertical cup:disc ratio 0.6 0.6 0.5 0.5 
Max IOP (mm Hg) 23 23 15 16 
CCT (um) 534 519 557 552 
Axial length (mm) 22.03 22.43 23.44 23.49 
Surgery PI PI - - 
 Supplementary Table 2. ASPH variants associated with anterior segment dysgenesis 
phenotype 
Position of each predicted pathogenic variant with the human genome (hg19 reference), 
consensus transcript (NM_004318), and protein (NP_004309) described using HGVS 
nomenclature (version 15.11). Frequencies of each allele in the gnomAD r2.0.2 database is 
shown, as are CADD, PolyPhen-2, and SIFT scores with predictions of deleteriousness. AF, 
allele frequency; D, deleterious; T, tolerated. 
 
gDNA (hg19) 
cDNA 
(NM_004318) exon 
protein 
(NP_004309) 
gnomAD r2.0.2 
AF 
CADD_
phred 
PP2_
HVA
R SIFT 
g.8:62430660C>A c.1836C>A 23 p.Cys641Ter . 37 . . 
g.8:62415991G>A c.2117G>A 25 p.Arg735Gln 
4/242206 
(0.00001651) 35 1; D 0.018; D 
 
 
Supplementary Table 3. Putative substrates of ASPH 
Genomic coordinates (hg19), associated human phenotypes and mouse orthologs, and 
numbers of predicted hydroxylation motifs in each full-length protein. 
 
Symbol Ensembl Gene ID Length ASPH motifs 
ADGRE1 ENSG00000174837 886 6 
ADGRE2 ENSG00000127507 823 4 
ADGRE3 ENSG00000131355 652 1 
ADGRE4P ENSG00000268758 457 1 
ADGRE5 ENSG00000123146 835 4 
ADGRL4 ENSG00000162618 690 1 
BMP1 ENSG00000168487 986 2 
C1R ENSG00000159403 705 1 
C1S ENSG00000182326 688 1 
CCBE1 ENSG00000183287 406 1 
CD248 ENSG00000174807 757 1 
CD93 ENSG00000125810 652 3 
CELSR1 ENSG00000075275 3014 2 
CELSR2 ENSG00000143126 2923 2 
CELSR3 ENSG00000008300 3312 1 
CLEC14A ENSG00000176435 490 1 
CRB1 ENSG00000134376 1406 10 
CRB2 ENSG00000148204 1285 7 
 CRELD1 ENSG00000163703 420 1 
CRELD2 ENSG00000184164 353 1 
CUBN ENSG00000107611 3623 4 
DLK1 ENSG00000185559 383 1 
DLK2 ENSG00000171462 383 2 
DLL1 ENSG00000198719 723 3 
DLL4 ENSG00000128917 685 1 
DNER ENSG00000187957 737 2 
EDIL3 ENSG00000164176 480 1 
EFEMP1 ENSG00000115380 493 4 
EFEMP2 ENSG00000172638 443 4 
EGF ENSG00000138798 1207 3 
EGFL6 ENSG00000198759 553 3 
EGFL7 ENSG00000172889 273 1 
EGFL8 ENSG00000241404 293 1 
EYS ENSG00000188107 3165 7 
F10 ENSG00000126218 488 1 
F7 ENSG00000057593 466 1 
F9 ENSG00000101981 461 1 
FAT1 ENSG00000083857 4588 1 
FAT3 ENSG00000165323 4589 1 
FAT4 ENSG00000196159 4981 2 
FBLN1 ENSG00000077942 703 4 
FBLN2 ENSG00000163520 1184 5 
FBLN5 ENSG00000140092 448 4 
FBLN7 ENSG00000144152 439 1 
FBN1 ENSG00000166147 2871 43 
FBN2 ENSG00000138829 2912 43 
FBN3 ENSG00000142449 2809 41 
GAS6 ENSG00000183087 721 4 
HEG1 ENSG00000173706 1381 1 
HMCN1 ENSG00000143341 5635 5 
HMCN2 ENSG00000148357 5059 3 
JAG1 ENSG00000101384 1218 10 
 JAG2 ENSG00000184916 1238 10 
LDLR ENSG00000130164 860 2 
LRP1 ENSG00000123384 4544 3 
LRP1B ENSG00000168702 4599 4 
LRP2 ENSG00000081479 4655 4 
LRP4 ENSG00000134569 1905 1 
LRP8 ENSG00000157193 963 2 
LTBP1 ENSG00000049323 1721 13 
LTBP2 ENSG00000119681 1821 13 
LTBP3 ENSG00000168056 1303 11 
LTBP4 ENSG00000090006 1624 14 
MASP1 ENSG00000127241 699 1 
MASP2 ENSG00000009724 686 1 
MATN2 ENSG00000132561 956 9 
MATN4 ENSG00000124159 622 2 
MEGF6 ENSG00000162591 1541 4 
MEGF8 ENSG00000105429 2845 2 
MMRN1 ENSG00000138722 1228 1 
NCAN ENSG00000130287 1321 1 
NELL1 ENSG00000165973 810 3 
NELL2 ENSG00000184613 816 3 
NID1 ENSG00000116962 1247 3 
NID2 ENSG00000087303 1375 3 
NOTCH1 ENSG00000148400 2555 22 
NOTCH2 ENSG00000134250 2471 22 
NOTCH2NL ENSG00000213240 236 1 
NOTCH3 ENSG00000074181 2321 18 
NOTCH4 ENSG00000204301 2003 11 
NPNT ENSG00000168743 565 3 
NRXN1 ENSG00000179915 1477 1 
NRXN3 ENSG00000021645 1643 1 
OIT3 ENSG00000138315 545 1 
PROC ENSG00000115718 461 1 
PROS1 ENSG00000184500 676 4 
 PROZ ENSG00000126231 400 1 
SCUBE1 ENSG00000159307 988 6 
SCUBE2 ENSG00000175356 999 6 
SCUBE3 ENSG00000146197 993 6 
SLIT1 ENSG00000187122 1534 2 
SLIT2 ENSG00000145147 1529 2 
SLIT3 ENSG00000184347 1523 2 
SNED1 ENSG00000162804 1413 5 
SUSD1 ENSG00000106868 747 2 
SVEP1 ENSG00000165124 3571 6 
THBD ENSG00000178726 575 2 
TLL1 ENSG00000038295 1013 2 
TLL2 ENSG00000095587 1015 2 
TPO ENSG00000115705 933 1 
UMOD ENSG00000169344 640 2 
UMODL1 ENSG00000177398 1318 3 
VCAN ENSG00000038427 3396 1 
VLDLR ENSG00000147852 873 2 
VWCE ENSG00000167992 955 3 
 
 
Supplementary Table 4. Clinical analytes associated with predicted ASPH substrates 
Predicted ASPH substrates and their relevant clinical analytes as measured in the ASPH 
compound heterozygous proband at last follow-up (aged 18 years). Units and laboratory normal 
ranges are shown for reference. 
 
Predicted ASPH 
substrate(s) Analyte 
Valu
e Units 
Normal 
range 
F7, F9, F10, PROC, PROS1 Prothrombin time 15 s (12-16) 
 Prothrombin INR 1.2 ratio (0.9-1.2) 
 Activated partial thromboplastin time 34 s (24-38) 
TPO Thyroid stimulating hormone 0.95 mIU/L (0.50-4.50) 
 Free T4 18 pmol/L (10-20) 
 Free T3 5.1 pmol/L (3.1-5.4) 
 Thyroid peroxidase antibody <5 IU/mL (<=49) 
LDLR HDL cholesterol 1.4 mmol/L (1.0-2.2) 
  LDL cholesterol 2.2 mmol/L (0.0-3.7) 
 non-HDL cholesterol 2.6 mmol/L  
 Total:HDL cholesterol 2.9 ratio (0.0-5.0) 
 Total triglycerides 0.9 mmol/L (0.3-2.0) 
(Complete blood count) Hemoglobin 129 g/L (115-155) 
 White cell count 7.8 x10e9/L (4.0-11.0) 
 Platelet count 498 x10e9/L (150-450) 
 Red blood cells 4.72 x10e12/L (3.8-5.2) 
 Neutrophils 4.5 x10e9/L (1.8-7.5) 
 Lymphocytes 2.6 x10e9/L (1.5-3.5) 
 Monocytes 0.53 x10e9/L (0.2-0.8) 
 Eosinophils 0.1 x10e9/L (0.02-0.5) 
 Basophils 0.02 x10e9/L (<=0.10) 
 
